Azalea Therapeutics Leverages Nature Publication to Advance In Vivo CAR T Platform

New updates have been reported about Azalea Therapeutics.

Azalea Therapeutics is accelerating development of its in vivo CAR T pipeline following publication in Nature of foundational research that underpins the company’s platform for site-specific genomic integration in T cells. The study, led by Azalea co-founders from UCSF and UC Berkeley, demonstrates that a two-vector system using Enveloped Delivery Vehicles and T cell–tropic AAVs can insert large DNA cargos directly into the TRAC locus in vivo.

In preclinical humanized mouse models, the approach generated physiologically regulated TRAC-CAR T cells that expanded robustly, reached therapeutic levels of CAR-positive cells, and achieved durable tumor control and B cell aplasia after a single administration. Azalea’s leadership states that these data form the scientific basis for its proprietary EDV-based platform, which aims to bypass ex vivo manufacturing, reduce complexity, and enable scalable, in vivo–generated CAR T therapies across cancer, autoimmune disease, and genetic disorders as programs advance toward IND-enabling studies.